Journal Article

DZNE-2020-07649

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition.

Lopez-Atalaya, J. P. (Corresponding author) ; Ito, S. ; Valor, L. M. ; Benito, E.DZNE* ; Barco, A.

2013
Oxford Univ. Press57750 Oxford

This record in other databases:    

Please use a persistent id in citations: doi:10.1093/nar/gkt590

Abstract: Histone deacetylase inhibitors (HDACis) have been shown to potentiate hippocampal-dependent memory and synaptic plasticity and to ameliorate cognitive deficits and degeneration in animal models for different neuropsychiatric conditions. However, the impact of these drugs on hippocampal histone acetylation and gene expression profiles at the genomic level, and the molecular mechanisms that underlie their specificity and beneficial effects in neural tissue, remains obscure. Here, we mapped four relevant histone marks (H3K4me3, AcH3K9,14, AcH4K12 and pan-AcH2B) in hippocampal chromatin and investigated at the whole-genome level the impact of HDAC inhibition on acetylation profiles and basal and activity-driven gene expression. HDAC inhibition caused a dramatic histone hyperacetylation that was largely restricted to active loci pre-marked with H3K4me3 and AcH3K9,14. In addition, the comparison of Chromatin immunoprecipitation sequencing and gene expression profiles indicated that Trichostatin A-induced histone hyperacetylation, like histone hypoacetylation induced by histone acetyltransferase deficiency, had a modest impact on hippocampal gene expression and did not affect the transient transcriptional response to novelty exposure. However, HDAC inhibition caused the rapid induction of a homeostatic gene program related to chromatin deacetylation. These results illuminate both the relationship between hippocampal gene expression and histone acetylation and the mechanism of action of these important neuropsychiatric drugs.

Keyword(s): Acetylation: drug effects (MeSH) ; Animals (MeSH) ; Binding Sites (MeSH) ; Chromatin: drug effects (MeSH) ; Chromatin: metabolism (MeSH) ; Chromosome Mapping (MeSH) ; Female (MeSH) ; Gene Expression Profiling (MeSH) ; Genomics (MeSH) ; Hippocampus: drug effects (MeSH) ; Hippocampus: metabolism (MeSH) ; Histone Deacetylase Inhibitors: pharmacology (MeSH) ; Histones: metabolism (MeSH) ; Hydroxamic Acids: pharmacology (MeSH) ; Methylation (MeSH) ; Mice (MeSH) ; NF-kappa B: metabolism (MeSH) ; Transcription, Genetic: drug effects (MeSH) ; Chromatin ; Histone Deacetylase Inhibitors ; Histones ; Hydroxamic Acids ; NF-kappa B ; trichostatin A

---

Contributing Institute(s):

1. Epigenetics and Systems Medicine in Neurodegenerative Diseases (AG Fischer)

Research Program(s):

1. 342 - Disease Mechanisms and Model Systems (POF3-342) (POF3-342)

Appears in the scientific report 2013

---

Database coverage:
; ; ; ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; IF >= 10 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; PubMed Central ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---